Science & Technology
Science and Technology
Science and Technology
Mon, August 20, 2012
Sun, August 19, 2012
Fri, August 17, 2012 CardioComm Solutions Partners with the Heart and Stroke Foundation of Canada on Atrial Fibrillation Detection and Stoke Prevent
August 17, 2012 14:34 ET
CardioComm Solutions Partners with the Heart and Stroke Foundation of Canada on Atrial Fibrillation Detection and Stoke Prevention Initiative in Toronto
First of a Series of Collaborative Programs to Use ECGs to screen for Atrial Fibrillation and Provide Community Use Validation of CardioComm Solution's Smart Monitoring Solution (SMS) to be Launched in the Fall of this Year
TORONTO, ONTARIO--(Marketwire - Aug. 17, 2012) -CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") and its flagship FDA cleared HeartCheck™ ECG monitor will be highly visible at today's launch of the Heart and Stroke Foundation of Canada's (Heart and Stroke) electrocardiogram ("ECG") based screening program for the detection of atrial fibrillation (AF) and other arrhythmias, being run at the Canadian National Exhibition in Toronto.
"In anticipation of our of full scale go-to-market plans in the Fall of 2012 with our Smart Monitoring Solution and the HeartCheck™ PEN, we have become involved in a series of joint programs with organizations like the Heart and Stroke," said Etienne Grima, Chief Executive Officer of CardioComm Solutions. "These programs will help validate our Smart Monitoring Solution and to extend it to other agencies and organizations interested in implementing community based health screening programs," Grima added.
For select visitors to the booth, personnel will perform wrist pulse checks and ECG recordings on persons 65 years and older, the age group with heightened risk for AF and therefore stroke incidence. A comparison will be made between the ability for pulse detection of an irregular heart rate versus the use of an ECG to identify the presence of an arrhythmia. In addition to this comparison, CardioComm Solutions will read the ECGs to classify the types of arrhythmia that may be present. Additional information will be collected from the participants with their consent to provide general health status information which will permit the potential identification of risk factors for and characteristics of any arrhythmias detected.
The national initiative organized by the Heart and Stroke and sponsored by Bayer HealthCare and Boehringer Ingelheim, anticipates screening a large number of people (up to 10,000) at four different events across Canada between August and November and should lead to developing a better understanding of the underlying arrhythmia and AF burden in the Canadian population. For CardioComm Solutions the benefits from this real world, in-field validation of its software and HeartCheck™ technologies will be a clinical validation of the Smart Monitoring solution in addition to a public introduction for the ease of use of the HeartCheck™ ECG devices.
"We will be hitting the consumer market with the first of its kind FDA-cleared HeartCheck™ PEN device and our Smart Monitoring software very shortly. Field trials such as these provide critical feedback in ensuring the long term success of our upcoming launch," noted Simi Grosman, member of the Company's Board of Directors. "This also is the first step in our development of arrhythmia detection field kits which will include the HeartCheck™ ECG monitors as well as the unlocked HeartCheck™ PENs. These self contained kits can be shipped to any screening group effecting community-based screening and education initiatives in the world. Each kit will provide devices, DVD instructions, upload directions to pre-established C4 data stores specific to the customer's intended use and geographic location as well as full ECG reading and interpretation services. We have named this remote access ECG diagnostic solution the SAFE (Screen for Atrial Fibrillation Everywhere) Program and are including this in our global HeartCheck™ marketing efforts," added Mr. Grosman.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
About The Heart and Stroke Foundation
The Heart and Stroke Foundation of Canada, a volunteer-based health charity, leads in eliminating heart disease and strokes and reducing their impact through the advancement of research and its application, the promotion of healthy living and advocacy.
Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
